申请人:Lowe Adams John
公开号:US20050080100A1
公开(公告)日:2005-04-14
This invention relates to a series of pyridylamino compounds of the formula I wherein Z
1
, Z
2
, W, X, Y and R
1
are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
本发明涉及一系列具有公式I的吡啶氨基化合物,其中Z1,Z2,W,X,Y和R1的定义如规范中所述,这些化合物表现出甘氨酸转运抑制剂的活性,其药学上可接受的盐,含有它们的制药组合物,以及它们在哺乳动物中,包括人类,用于增强认知和治疗正性和负性精神分裂症和其他精神病症状的用途。